Kabi, Mylan and Neptune Thwarted In US Pemetrexed Proceedings
Executive Summary
A US vitamin-regimen patent protecting Lilly’s Alimta pemetrexed brand until 2022 is valid, the US Court of Appeals has ruled.
You may also be interested in...
Alimta ANDA Products Hit Double Digits With Several Launches
Following patent expiry on 24 May, Alimta ANDA products have reached the US market, eating into a product that generated more than $1.2bn in sales last year.
Doctrine Of Equivalents Trips Reddy’s And Pfizer On Pemetrexed
Hybrid 505(b)(2) rivals to Lilly’s Alimta from Dr Reddy’s and Pfizer do not literally infringe a key method-of-treatment patent protecting the pemetrexed brand until May 2022. But their alternative salts infringe under the doctrine of equivalents, the US Court of Appeals has confirmed.
Pressure Mounts For German Tender Reforms
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.